Abstract:Mutant isocitrate dehydrogenase 1 (mIDH1) is a common driving factor in acute myeloid leukemia (AML), with the R132 mutation accounting for a high proportion. The U.S. Food and Drug Administration (FDA) approved Ivosidenib, a molecular entity that targets IDH1 with R132 mutations, as a promising therapeutic option for AML with mIDH1 in 2018. It was of concern that the occurrence of disease resistance or recurrence, attributed to the IDH1 R132C/S280F second site mutation, was observed in certain patients treated with Ivosidenib within the same year. Furthermore, it should be noted that most mIDH1 inhibitors demonstrated limited efficacy against mutations at this specific site. Therefore, there is an urgent need to investigate novel inhibitors targeting mIDH1 for combating resistance caused by IDH1 R132C/S280F mutations in AML. This study aimed to identify novel mIDH1 R132C/S280F inhibitors through an integrated strategy of combining virtual screening and dynamics simulations. First, 2000 hits were obtained through structure-based virtual screening of the COCONUT database, and hits with better scores than −10.67 kcal/mol were obtained through molecular docking. A total of 12 potential small molecule inhibitors were identified through pharmacophore modeling screening and Prime MM-GBSA. Dynamics simulations were used to study the binding modes between the positive drug and the first three hits and IDH1 carrying the R132C/S280F mutation. RMSD showed that the four dynamics simulation systems remained stable, and RMSF and Rg showed that the screened molecules have similar local flexibility and tightness to the positive drug. Finally, the lowest energy conformation, hydrogen bond analysis, and free energy decomposition results indicate that in the entire system the key residues LEU120, TRP124, TRP267, and VAL281 mainly contribute van der Waals forces to the interaction, while the key residues VAL276 and CYS379 mainly contribute electrostatic forces.

Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening

Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study

Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor

Identification of New IDH2R140Q Inhibitors by Discriminatory Analysis‐based Molecular Docking and Biological Evaluation

Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations

Identification of New Inhibitors of Mutant Isocitrate Dehydrogenase 2 through Molecular Similarity-based Virtual Screening

Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation

3D-QSAR, Molecular Docking and Molecular Dynamics Simulations Study of 3-Pyrimidin-4-yl-oxazolidin-2-one Derivatives to Explore the Structure Requirements of Mutant IDH1 Inhibitors

3D-QSAR and Docking Studies on 1-Hydroxypyridin-2-one Compounds As Mutant Isocitrate Dehydrogenase 1 Inhibitors

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment

Discovery of novel ID2 antagonists from pharmacophore-based virtual screening as potential therapeutics for glioma

3D-QSAR, Scaffold Hopping, Virtual Screening, and Molecular Dynamics Simulations of Pyridin-2-one as mIDH1 Inhibitors

Discovery and Optimization of 2 H -1λ 2 -Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer

Computational study on novel natural compound inhibitor targeting IDH1_R132H

Design, Synthesis and Biological Activity of 3-Pyrazine-2-yl-oxazolidin-2-ones As Novel, Potent and Selective Inhibitors of Mutant Isocitrate Dehydrogenase 1.

Comprehensive Exploration of Isocitrate Dehydrogenase (IDH) Mutations: Tumorigenesis, Drug Discovery, and Covalent Inhibitor Advances

Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma

Discovery of novel IDO1 inhibitors via structure-based virtual screening and biological assays

Discovery of Cyanopyridine Scaffold As Novel Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors Through Virtual Screening and Preliminary Hit Optimisation.

Sequence-structure functional implications and molecular simulation of high deleterious nonsynonymous substitutions in IDH1 revealed the mechanism of drug resistance in glioma